Background: The impact of disease and treatment on the patient’s overall well-being and functioning is a topic of growing interest in clinical research and practice. The aim of this study is to obtain reference data on quality of life of Croatian general population. Further, we aim to assess the impact of the disease and its primary systemic treatment on their health related quality of life (HrQoL) in multiple myeloma (MM) patients. ----- Patients and methods: Participants for the first part of the study were randomly selected from adult Croatian population. In the clinical part of the study MM patients were included as prospectively diagnosed within two years in two major Croatian haematological centres. The EORTC QLQ-C30 in both trials ...
Objective: The situation of patients with multiple myeloma, whose treatment often implies high-dose ...
Background Health-related quality of life (HRQOL) is a key aspect for chronic myeloid leukemia (CML)...
ObjectivesThresholds for the minimally important difference (MID) or responder definition (RD) in he...
The impact of disease and treatment on the patient’s overall well-being and functioning is a topic o...
Unfortunately, multiple myeloma is still an incurable disease. The therapeutic aim is to reduce tumo...
Background: Reliable and validated instruments are needed in order to study the quality of life in m...
SummaryBackgroundQuality of life (QoL) is defined as “a patient's subjective evaluation of his life ...
Background Multiple myeloma (MM) is the third most common hematologic malignancy with increasing im...
The objectives of this study were to compare health-related quality of life (HRQOL) between multiple...
Objective:The aim of this study was the validation of the European Organization for Research and Tre...
Background: Reliable and validated instruments are needed in order to study the quality of life in m...
Im Rahmen dieser Studie wurde die Lebensqualität (QoL) von Patienten mit Multiplem Myelom zu verschi...
The aim of this study was to determine the prevalence of symptoms and problems in hospitalized hemat...
Background: Health-related quality of life (HRQOL) is a key aspect for chronic myeloid leukemia (CML...
In the Medical Research Council (MRC) Myeloma IX trial (ISRCTN684564111) patients were randomised to...
Objective: The situation of patients with multiple myeloma, whose treatment often implies high-dose ...
Background Health-related quality of life (HRQOL) is a key aspect for chronic myeloid leukemia (CML)...
ObjectivesThresholds for the minimally important difference (MID) or responder definition (RD) in he...
The impact of disease and treatment on the patient’s overall well-being and functioning is a topic o...
Unfortunately, multiple myeloma is still an incurable disease. The therapeutic aim is to reduce tumo...
Background: Reliable and validated instruments are needed in order to study the quality of life in m...
SummaryBackgroundQuality of life (QoL) is defined as “a patient's subjective evaluation of his life ...
Background Multiple myeloma (MM) is the third most common hematologic malignancy with increasing im...
The objectives of this study were to compare health-related quality of life (HRQOL) between multiple...
Objective:The aim of this study was the validation of the European Organization for Research and Tre...
Background: Reliable and validated instruments are needed in order to study the quality of life in m...
Im Rahmen dieser Studie wurde die Lebensqualität (QoL) von Patienten mit Multiplem Myelom zu verschi...
The aim of this study was to determine the prevalence of symptoms and problems in hospitalized hemat...
Background: Health-related quality of life (HRQOL) is a key aspect for chronic myeloid leukemia (CML...
In the Medical Research Council (MRC) Myeloma IX trial (ISRCTN684564111) patients were randomised to...
Objective: The situation of patients with multiple myeloma, whose treatment often implies high-dose ...
Background Health-related quality of life (HRQOL) is a key aspect for chronic myeloid leukemia (CML)...
ObjectivesThresholds for the minimally important difference (MID) or responder definition (RD) in he...